Humoral immune response against p53 protein in patients with colorectal carcinoma
β Scribed by Katerina Angelopoulou; Michael Stratis; Eleftherios P. Diamandis
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- French
- Weight
- 156 KB
- Volume
- 70
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
β¦ Synopsis
p53 aberrations are frequent in colorectal carcinogenesis (40-70%). Because p53 gene mutations typically result in increased p53 protein concentration in tumor cells, this cellular protein might become immunogenic during tumor development. To test this hypothesis, serum p53 antibodies were quantitatively analyzed in 229 patients with colorectal cancer, using an immunofluorometric procedure. Circulating antibodies against p53 were found in 23% (53/229) of the patients. We quantified antibody concentrations in all positive sera and found that they varied from 300 to 500,000 arbitrary units/l. Sequential analysis of positive sera from 3 patients showed that p53 antibody concentrations change during the course of the disease, reflecting progression or regression. No association was found between the presence of p53 antibodies and age, sex, stage, histological grade and patient relapse-free or overall survival. These data demonstrate that antibody generation against the p53 tumorsuppressor protein is a relatively common event in colorectal cancer and that serological analysis for p53 antibodies may have some value for patient monitoring. The test has no value for prognosis.
π SIMILAR VOLUMES
## BACKGROUND. Humoral hypercalcemia rarely is associated with colorectal carcinoma; to the authors' knowledge only nine cases have been reported to date. ## METHODS. Two cases of advanced colorectal carcinoma with humoral hypercalcemia of malignancy (HHM) are presented. ## RESULTS. The two
The p21 protein inhibits cyclin-dependent kinases and mediates cell-cycle arrest and cell differentiation. It is induced by wild-type p53, but not by mutant p53. This study of 75 patients with endometrial carcinoma investigates the relationship between p21 expression and the functional status of p53
## BACKGROUND. The appearance of p53 mutations in colorectal carcinoma was determined, independent of differentiation and tumor stage of the primary tumors, in relation to the survival of patients who were scheduled to undergo liver resection. ## METHODS. Tumor material was analyzed for p53 mut